Agilent Technologies Inc. has made an announcement regarding a collaboration with Incyte. The agreement will merge Agilent's proficiency in developing companion diagnostics with the development and commercialization of Incyte's offerings in hematology and oncology. Agilent will use this opportunity to further grow its companion diagnostics portfolio with biomarkers, while Incyte will utilize Agilent's expertise in the areas of IVD assay development, achieving global regulatory approvals, and product commercialization. This will be beneficial in supporting clinical trials, as well as potentially aiding registration and commercialization of CDx in both the US and Europe.
Paul Beresford, the general manager of Agilent's Companion Diagnostics Division, shared his views on the agreement. He expressed hope that this collaboration between Agilent and Incyte could speed up the production of inventive precision medicine products. Such developments could significantly enhance patient health outcomes.
For additional health news like this, visit rttnews.com.
